Lighthouse II study finished recruitment phase with more than 400 participants
The Lighthouse II study finished recruiting. With currently 419 participants in the…
![Resta in [u]contatto[/u]](/paper-plane.svg)
Innovations in ALS clinical trials through the TRICALS Academy
Last month marked a significant moment for the TRICALS Academy, as the…
Your expert opinion wanted on ALS clinical trials
TRICALS aims to improve clinical research to finding a cure for ALS.…
European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen.…
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label…
Meet the centre – Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe.…
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug…
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study,…
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study.…
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European…